... creating a leading global biologic company

Regeneration Technologies and Tutogen
announce plans to merge

Overview

Regeneration Technologies, Inc (RTIX) and Tutogen Medical, Inc. (TTG) announced on November 13, 2007 a merger to create the leading provider of sterile biologic solutions for patients around the world, reaching a broad range of markets with a diversified mix of implants and distribution channels.

"When comparing the similarities between Tutogen and RTI – our commitment to safety and sterilization of biologics, our responsibility to honoring donor families and helping recipients, and our culture of growth to meet the needs of surgeons around the world – it is easy to see how these two companies will fit very nicely together," said Brian K. Hutchison, RTI chairman, president and CEO. "Guy Mayer and the management team at Tutogen have done an outstanding job in the past two years of realigning their company and product lines, as well as optimizing their distribution channels to set the stage for continued growth in the years to come."

"We believe that our strength in the tissue membrane markets and our expertise in xenograft applications will blend perfectly with RTI’s strength in innovation and leadership in the orthopedics markets," said Guy Mayer, Tutogen’s president and chief executive officer. "Each company’s complementary strengths would create a very well-balanced leader in the biologics industry."

Just the Facts

Terms of the Deal:

• Tax-free, stock-for-stock exchange
• Tutogen shareholders will receive 1.22 shares of newly issued RTI common stock in exchange for each share of Tutogen common stock they own
• Expect to close in Q1 2008 subject to regulatory and other customary conditions
• Proforma ownership of the combined company*:
• Approx. 55 percent RTI shareholders and approx. 45 percent Tutogen shareholders
• 56 million shares outstanding

* of the company on a diluted basis

Combined Company

• Headquarters: Alachua, Fla. with offices in United States, Germany and France
• Approx. 750 employees
• Proprietary, validated BioCleanse® and Tutoplast® tissue sterilization processes